XML 68 R54.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Collaborative and Licensing Agreements - Revenue Recognition (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | $ 275,111 | $ 122,694 | $ 156,700
Deferred revenue | 37,300 | 92,600 |
Research collaboration |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 93,000 | 4,500 | 16,300
Milestone |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 21,000 | 50,200 | 23,200
Licensing |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 80,800 | 50,200 | 112,200
Royalties |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 80,300 | 17,800 | 5,000
Aimmune |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded |  | 9,600 |
Alexion Pharmaceuticals, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 22,200 | 26,200 | 13,000
Amgen, Inc. |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded |  |  | 5,000
Astellas |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded |  | 3,500 | 14,000
Genentech |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 2,500 | 3,500 | 113,900
Gilead |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded |  | 13,500 |
Janssen |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 113,800 |  |
MorphoSys |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 18,400 | 39,000 |
Novartis |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 43,100 |  | 10,000
MiRagen/Viridian |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 7,500 | 6,000 |
Omeros |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded |  | 5,000 |
Vir |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | 52,700 | 300 | $ 800
Zenas Bio Pharma Limited |  |  |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |
Revenue recorded | $ 14,900 | $ 16,100 |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_CollaborationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xncr_MilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AimmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_AstellasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GenentechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_GileadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_JanssenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_MiragenViridianMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_OmerosCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_VirBiotechnologyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xncr_ZenasBioPharmaLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |